Tuesday, 24 June 2025
  
Login

Australia's most trusted
source of pharma news

Tuesday, 24 June 2025
News

TGA approves new heart drug

Posted 23 June 2025 AM

The TGA has approved a short-acting, ultra-high selective beta-1 adrenoreceptor blocker called Rapiblyk sponsored by Phebra.

Administered via intravenous infusion, Rapiblyk is indicated in adults for supraventricular tachycardia and for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (7)

Clinical & Medical, R&D (11)

Regulatory, Pharmacovigilance & QA (2)

Other (13)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.